Pre-ADCOM and Advisory Committee
Track how the evidence around a drug is shifting in the months before an FDA advisory committee meeting.
What is hardening: Which clinical claims have the strongest supporting evidence going into the ADCOM?
What is weakening: Which claims have lost citations, been reverted, or had their evidence base narrow?
What remains contested: Which safety or efficacy points are still under active editorial dispute?